What is ruxolitinib and what are its side effects?

What is Ruxolitinib?

Ruxolitinib is a potent and selective oral Janus kinase (JAK) 1 and JAK2 inhibitor approved for treating myeloproliferative neoplasms, specifically polycythemia vera (PV) in patients who are resistant to or intolerant of hydroxyurea, and myelofibrosis. 1, 2 It is also available as a topical 1.5% cream formulation for atopic dermatitis. 3

Mechanism and Clinical Use

Ruxolitinib works by inhibiting the JAK-STAT signaling pathway, which is aberrantly activated in myeloproliferative neoplasms due to JAK2 mutations (particularly JAK2V617F). 4 This targeted inhibition addresses the underlying pathophysiology of these diseases.

FDA-Approved Indications for Oral Ruxolitinib:

• Polycythemia vera: For patients with inadequate response to or intolerance of hydroxyurea (FDA approval 2014, EMA approval 2015) 1, 2
• Myelofibrosis: FDA approval in 2011, EMA approval in 2012 4

Clinical Efficacy in PV:

In the pivotal RESPONSE trial, ruxolitinib demonstrated superior outcomes compared to standard therapy 2, 5:

• 60% achieved hematocrit control without phlebotomy (vs. 20% with standard therapy)
• 38% achieved ≥35% spleen volume reduction (vs. 1% with standard therapy)
• 49% achieved ≥50% reduction in symptom burden (vs. 5% with standard therapy)
• 24% achieved complete hematologic remission (vs. 9% with standard therapy)

Side Effects of Ruxolitinib

Serious Side Effects (Black Box Warnings for JAK Inhibitors)

The FDA has issued boxed warnings for JAK inhibitors as a class, though these apply primarily to oral formulations 3:

1. Serious Infections

• Increased susceptibility to bacterial, fungal, and viral infections including tuberculosis and disseminated infections
• Herpes zoster (shingles) reactivation: Occurred in 6% of ruxolitinib-treated PV patients vs. 0% in controls 2, 5
• Late-onset opportunistic infections including disseminated mycobacterial disease have been reported with long-term use 6
• Do not initiate ruxolitinib in patients with active serious infections 3

2. Malignancies

• Non-melanoma skin cancer (NMSC): 19.4% incidence in long-term users (≥3 years) 6
• Increased risk of lymphomas and other cancers, particularly in current or past smokers 3
• Regular skin examinations are mandatory during treatment 3

3. Major Adverse Cardiovascular Events (MACE)

• Increased risk of heart attack, stroke, and cardiovascular death in patients ≥50 years with cardiovascular risk factors 3
• Particularly elevated in current or past smokers 3

4. Thrombosis

• Deep vein thrombosis (DVT) and pulmonary embolism (PE) can occur 3
• Paradoxically, thromboembolic events were lower with ruxolitinib (1.8%) compared to standard therapy (8.2%) in PV trials 2

5. Increased Mortality

• Increased risk of death from any cause in patients ≥50 years with cardiovascular risk factors taking oral JAK inhibitors 3

Common Hematologic Side Effects

Myelosuppression is the most common dose-limiting toxicity 7, 4:

• Anemia: Grade 3/4 occurred in 2% of PV patients 2, 5
• Thrombocytopenia: Grade 3/4 occurred in 5% of PV patients 2
• Neutropenia: Can occur but less common 4
• These are typically grade 1-2 and manageable with dose adjustments 8

Common Non-Hematologic Side Effects

From clinical trials in PV patients 8, 5:

• Headache
• Diarrhea
• Pruritus
• Fatigue
• Hyperlipidemia 7

Long-Term Safety Considerations

With extended therapy (≥3 years), specific risks emerge 6, 7:

• NMSC and herpes zoster are the most significant long-term concerns
• No significant increase in secondary malignancies other than NMSC 6
• Increased rates of urinary tract infections, pneumonia, and sepsis 6

Critical Clinical Caveats

Drug Interactions:

• Ruxolitinib is metabolized through CYP3A4 4
• Dose adjustment required with potent CYP3A4 inhibitors
• Consider drug-drug interactions carefully

Monitoring Requirements:

• Regular complete blood counts for myelosuppression
• Tuberculosis screening before initiation 3
• Regular skin examinations 3
• Monitor for signs of infection, cardiovascular events, and thrombosis

Special Populations:

• Pregnancy: Avoid; switch to interferons if cytoreduction needed 2
• Breastfeeding: Avoid during treatment and for 4 weeks after last dose 3
• Age ≥50 with CV risk factors: Heightened vigilance for MACE and mortality risk 3

Topical Formulation Note:

The 1.5% cream formulation has significantly lower systemic absorption than oral ruxolitinib, with plasma concentrations below the threshold for JAK-mediated myelosuppression 9, 10. The boxed warning for topical ruxolitinib may be overly cautious given its pharmacokinetic profile, though it remains in place due to FDA class labeling requirements.